



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/666,366		09/19/2003	Fen Huang	34506.143	8954
	75	90 03/15/2006	EXAMINER		
	Joseph T. Leon	ne	HUTSON, RICHARD G		
	DEWITT ROSS	S & STEVENS S.C.			
	US Bank Buildi	ng	ART UNIT	PAPER NUMBER	
		Drive, Suite 401	1652		
	Madison, WI	53717-1914			

DATE MAILED: 03/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

1		Application	on No.	Applicant(s)					
Office Action Summary		10/666,36)6	HUANG ET AL.					
		Examiner		Art Unit					
		Richard G	. Hutson	1652					
	The MAILING DATE of this communication a	ppears on the	cover sheet with the c	orrespondence ad	dress				
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
2a)□	Responsive to communication(s) filed on This action is FINAL . 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
4) Claim(s) 1-45 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-45 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	inder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/06 r No(s)/Mail Date	8)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite	O-152)				

Art Unit: 1652

DETAILED ACTION

Claims 1-45 are pending and at issue for examination.

DETAILED ACTION

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-9, 10-17, 18-25 and 40-45, drawn to methods of protecting RNA, inactivating RNases, storing RNA and inactivating a prokaryotic of plant RNase, classified in class 435, subclass 69.2.
- II. Claims 26-32 and 33-39, drawn to methods of performing RT-PCR and quantitative RT-PCR, classified in class 435, subclass 91.2.

For inventions I and II above, restriction to one of the following is also required under 35 USC 121.

Applicants are in addition to one of group I and II above, applicants are required to elect an invention corresponding to a source of the Rnase inhibitor protein to be used in the claimed methods (i.e. porcine, rat, human placental or recombinant human placental sources, etc...)

Applicants are additionally required to elect an invention corresponding to the type of RNase to be inactivated or protected from (i.e. RNAse A, RNase B, RNase C and RNase I, *E. coli* RNase etc...)

Claims 1-3, 6-8, 10-12, 15, 16, 18-20, 23-25, 26-29, 32, 33-35, 38, 39, 40 and 43-45 link(s) inventions corresponding to Groups I and II as well as those inventions

Art Unit: 1652

corresponding to the source of RNase inhibitor protein and type of RNase to be inactivated. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 1-3, 6-8, 10-12, 15, 16, 18-20, 23-25, 26-29, 32, 33-35, 38, 39, 40 and 43-45. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim(s) including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1652

The inventions corresponding to the RNase inhibitor protein and its source and the inventions corresponding to the type of RNase to be degraded are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different polypeptides and sources of structurally different polypeptides. Therefore, where structural identity is required, such as for hybridization or expression, the polypeptides have different effects.

Inventions I and II are directed to related methods. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the related methods of Group I and Group II involve different steps, for instance the RT-PCR methods involve a thermal-cycling step, and the related methods of Group I and Group II have different functions and effects. For instance, methods of group II results in the ultimate synthesis of a nucleic acid product, whereas the methods of Group I merely protects or maintains a nucleic acid product.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the literature

Art Unit: 1652

and sequence searches required for each of the Groups are not required for another of the Groups, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Hutson whose telephone number is 571-272-0930. The examiner can normally be reached on M-F, 7:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1652

Page 6

Richard G Hutson, Ph.D. Primary Examiner Art Unit 1652

rgh 3/7/2006